04/16/2024: Lab Update: Clarification for A/H5 Influenza Assay Licensing
Audience: Clinical Laboratory Professionals
Level: Laboratory Update
Since identifying a human case of A/H5 Influenza in Colorado in 2022, the CDC Influenza Division (ID) has been collaborating with relevant CDC offices and external commercial manufacturers to prepare the U.S. for commercial manufacturing of A/H5 assays in the event of a public health outbreak response. On April 15, 2024, CDC hosted a Laboratory Outreach Communication System (LOCS) Call which included a situational update and testing guidance for highly pathogenic Avian Influenza A(H5N1) virus. For clarification, CDC will not be providing its inventory of A/H5 tests to commercial diagnostic companies. If commercial developers of diagnostic tests are interested in a royalty-free license to the CDC’s FDA 510K cleared Influenza A/H5 Subtyping Diagnostic assay design, please contact flusupport@cdc.gov for further information.
We encourage you to share this message widely with your network(s).
Opt in to receive updates from the CDC Laboratory Outreach Communication System.
Online Resources
- Highly Pathogenic Avian Influenza A(H5N1) Virus in Animals: Interim Recommendations for Prevention, Monitoring, and Public Health Investigations | Avian Influenza (Flu)
- Health Alert Network (HAN) – 00506 | Highly Pathogenic Avian Influenza A(H5N1) Virus: Identification of Human Infection and Recommendations for Investigations and Response
Questions?
- If you are a clinical or public health laboratory professional, contact LOCS.
- For media inquiries, contact the CDC Newsroom.
- For all other questions, contact CDC-INFO.
Thank you,
The Laboratory Outreach Communication System
Laboratory Outreach Communication System (LOCS) | Division of Laboratory Systems (DLS)
Center for Laboratory Systems and Response (CLSR)
Centers for Disease Control and Prevention (CDC)